You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SBIR Phase I:Regolith size sorting technology for space resource utilization
SBC: Interlune Corporation Topic: SPThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a core enabling technology for lunar in situ resource utilization: the ability to sort “Moon dirt” (lunar regolith) by particle size. Size sorting is an important capability for nearly all in situ resource utilization activities that use lunar regolith as a feedstock material ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase II:Forecasting Battery Health and Maintenance using Data-Driven Predictive Analytics
SBC: ASTROLABE ANALYTICS INC Topic: AAThe broader impact of this Small Business Innovation Research (SBIR) Phase II project includes enhancing US economic competitiveness, improving the health and welfare of the American public, and developing the US technical workforce. The success of this project will have a direct impact on the manufacturers, integrators, and operators of battery-powered assets. Empowering battery engineering teams ...
SBIR Phase II 2023 National Science Foundation -
RNA aptamers for rapid response to COVID-19 variants
SBC: DOTQUANT LLC Topic: CDCABSTRACT The COVID-19 pandemic caused by SARS-CoV-2 viruses has had an unprecedented disruptive global impact. Although vaccination has been expected to end the spread, the fast mutations have increased the breakthrough infection rates in the fully vaccinated population. RNA viruses are known to have very high rates of mutation and evolution. The high rate of mutation is correlated with virulence ...
SBIR Phase I 2023 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment
SBC: En Solucion Inc Topic: FDARecent foodborne illness outbreaks traced to contaminated field harvesting equipment have highlighted the need for incorporating improved sanitization practices at the time of harvest. Field- harvested specialty crops represent 50% of the top ten foods linked to major recalls and outbreaks over the past five years. Proper sanitization of outdoor harvest equipment is made complicated by operational ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
Chromosomal aberration detection in FFPE tissue using proximity ligation sequencing
SBC: PHASE GENOMICS, INC. Topic: NCIABSTRACT The detection of chromosomal aberrations is a frontline diagnostic for the spectrum of blood neoplasms. Chromosomal aberrations, such as translocations, inversions, deletions and insertions, have been historically identified using cytogenetic methods or more recently through application of long read sequencing or optical mapping technologies. These methods have been less applicable in sol ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis
SBC: KULEANA TECHNOLOGY, INC. Topic: 400PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.
SBC: GELBCHEM, LLC Topic: NICHDProject Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Maren-go Airfield Autonomous Operations: FOD Retriever
SBC: MAREN-GO SOLUTIONS CORPORATION Topic: AF231D003To address the USAF need for FoD detection and retrieval, Maren-go Solutions proposes to develop a new Airfield Autonomous Operations - (A2O). This proposed Maren-go A2O is an improvement over the A2O currently focused on retrieval by net. The innovation
SBIR Phase II 2023 Department of DefenseAir Force -
Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma.
SBC: ORLANCE, INC Topic: NCIPROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted with cancer vaccines. However, technologies that can effectively deliver these cancer neoantigens an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins
SBC: TALUS BIOSCIENCE INC Topic: 400SUMMARY To evaluate how a drug candidate affects cells, researchers often study how the abundance or behavior of a specific set of proteins is changed by treatment with each compound. However, it is not currently possible to test the effect of every possible drug compound (rt500,000) on every human protein (~20,000) in hundreds of different types of cells. Even the most advanced protein analysis s ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health